Overview
Bevacizumab is a recombinant humanized monoclonal antibody that specifically binds to vascular endothelial growth factor (VEGF), a protein that plays a critical role in tumor angiogenesis. Developed by Genentech and marketed under the brand name Avastin, it was first approved by the FDA in 2004 for metastatic colorectal cancer. As an anti-angiogenic agent, bevacizumab works by starving tumors of their blood supply, thereby inhibiting growth and metastasis. This biologic drug represents a milestone in targeted cancer therapy, offering improved outcomes when combined with chemotherapy. Its development marked a shift from traditional cytotoxic treatments to precision medicine approaches. Bevacizumab is now included in treatment protocols for multiple cancers globally, with ongoing research exploring expanded indications.
Physical and Chemical Properties
Bevacizumab is a large glycoprotein with a complex structure comprising two light chains and two heavy chains connected by disulfide bonds. The antibody has a molecular weight of approximately 149 kilodaltons and is produced through recombinant DNA technology in Chinese hamster ovary (CHO) cells. The final drug product is formulated as a sterile, preservative-free solution for intravenous infusion. Key stability parameters include pH sensitivity (formulated at pH 6.2) and temperature constraints. The solution typically has an osmolality of 300 mOsm/kg and contains excipients like trehalose dihydrate and polysorbate 20. Aggregation and fragmentation are primary degradation concerns, necessitating strict storage conditions and handling protocols to maintain therapeutic efficacy.
Main Applications
In oncology, bevacizumab is approved for first-line treatment of metastatic colorectal cancer (combined with FOLFOX or FOLFIRI), non-squamous non-small cell lung cancer (with carboplatin/paclitaxel), and recurrent glioblastoma. It also shows efficacy in metastatic renal cell carcinoma (with interferon-alfa) and platinum-resistant ovarian cancer. Off-label uses include treatment of age-related macular degeneration (AMD) in ophthalmology, where it inhibits choroidal neovascularization. Emerging applications are being investigated for other solid tumors and inflammatory conditions. Treatment regimens vary by indication, typically administered at doses ranging from 5-15 mg/kg every 2-3 weeks. Response rates and progression-free survival benefits differ significantly across cancer types, necessitating biomarker-guided patient selection.
Safety and Storage
Bevacizumab carries black box warnings for gastrointestinal perforations, surgery-related wound healing complications, and severe hemorrhagic events. Common adverse effects include hypertension (managed with antihypertensives), proteinuria, fatigue, and nasal septum perforation. Regular monitoring of blood pressure, renal function, and wound status is mandatory during treatment. Proper storage requires refrigeration at 2-8°C without freezing. Unopened vials remain stable until the expiration date when stored correctly. Once prepared for infusion, the solution should be used within 8 hours when stored at 2-8°C or 4 hours at room temperature. Shipping must maintain cold chain integrity using validated thermal packaging with temperature monitoring devices.
B2B Procurement Guide
Pharmaceutical purchasers should prioritize GMP-certified manufacturers with proven biosimilar production capabilities if considering cost-effective alternatives. Key procurement factors include batch consistency, fill volume accuracy (typically 4 mL or 16 mL vials), and availability of stability data. Minimum order quantities often apply due to production scale requirements. Regulatory documentation should include Certificate of Analysis, Drug Master File access, and compliance with pharmacopeial standards (USP/EP). For international shipments, verify import licensing requirements and customs clearance procedures for biologic drugs. Consider demand forecasting carefully due to shelf life limitations (usually 24-36 months) and clinical usage patterns.